Corporate Presentation 0 Disclaimer Certain statements in this - - PowerPoint PPT Presentation

Corporate Presentation

1

Disclaimer

Certain statements in this document are forward looking based on management's current expectations but actual events may differ materially due to various factors. These statements are related but not limited to future objectives, plans, status, events, circumstances, progress and outcome of research and development, potential product attributes, usage, launch dates and sales potential, changes in the value of rupee and other foreign currencies and environmental changes. These forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and our reports to

• shareholders. The company assumes no obligation to update forward-looking statements to reflect

actual results, changed assumptions or other factors.

1

• Jubilant Bhartia Group : Valued around US $ 3Bn
• Employs around 30,000 people across the globe with ~ 1400 in North America
• Jubilant Bhartia Foundation, a not for profit organisation is a social arm of Jubilant Bhartia Group
• The foundation is engaged in community development work focusing on primary education, basic healthcare, skill

development through vocational training for youth & women

• Aims at long term sustainable social intervention by empowering communities through 4P model

(Public-Private-People-Partnership) Pharmaceuticals & Life Sciences

Integrated Outsourcing Solutions Provider for Pharmaceutical & Life Sciences Industry India’s largest CRAM s Company Revenues FY2012: US $ 892 M n (Rs.4,278 Crs) Listed on NSE & BSE, India Leading player in Agri Products in North India, Caters to niche markets in Performance Polymers globally 2nd largest retailer in Bengaluru operating 5 hypermarket-cum-malls Revenue FY 2012: US $ 207 M n (Rs. 996 Crs) Listed on NSE & BSE, India A master franchise of Domino’s Pizza for India, Bangladesh, Nepal & Sri Lanka and Dunkin’ Donuts for India; Domino’s has presence in 118 cities through over 552 stores in India 8 Dunkin’ Donuts stores

• pened since M ay 2012, in

Delhi NCR Revenues FY 2012: US$ 212 M n (Rs. 1,018 Crs) Listed on NSE & BSE, India Engaged in the upstream oil and gas exploration and production sector Portfolio of 9 blocks in India Producing Asset – Kharsang Development Asset – KG block Revenues FY 2012: US$ 19.06 M n (Rs. 92 Crs) Listed in AIM market, London Aerospace Sole authorized Independent Representative of Bell Helicopter in India for sales, marketing and customer support. Also represent other international aerospace companies. Oil & Gas Services

• Consultant to Transocean-
• ffshore drilling company
• M anning and M arketing

services for Tidewater M arine International etc

Agri & Polymers And Retail Food Oil & Gas Services

Exclusive dealership of Audi make cars in Karnataka and Tamil Nadu Service center for Audi cars in Bengaluru and Chennai Custom Paint and Body workshop in Bengaluru

Auto

Jubilant Bhartia Group - S napshot

3

Jubilant Life Sciences – Overview

* United Nations Conference on Trade And Development report 2010 ** March 2013

• Providing Pharmaceutical & Life Sciences

products and services across the pharmaceutical value chain

• Ranked No. 6 amongst top 10 Global Pharma
• utsourcing players as per UNCTAD* World

Investment Report 2011

• Reputed and High Quality relationships with

T

• p 20 Pharma companies, and 7 out of the

top 10 Agrochemical companies globally

• Low cost, multi location & vertically integrated

supplier

• Employs over 6300 people including 1400 in

North America and 1200 in R&D

• Part of Jubilant Bhartia Group, with founders

shareholding at 49 %* *

Integrated Pharmaceutical & Life Sciences Company ‘Partner of Choice’ to Global Life Sciences Companies

Domes tic 30% Interna tional 70%

Revenue M ix by Geography US $ 892 M n (Rs 4,278crs)

3

4

Global Presence

• Present in India, North America, Europe and China
• International sales in 98 countries
• 50% assets in North America

Gajraula, Uttar Pradesh Largest integrated pyridine & its derivatives facility in the world Ambarnath, M aharashtra Pyridine derivatives Bengaluru, Karnataka State-of-art Discovery Centre Roorkee, Uttarakhand UKM HRA, USFDA, PM DA, ANVISA approved facility for generics Samlaya, Gujarat Nutrition Products Nira, M aharashtra Life Sciences Chemicals Bharuch, Gujarat SEZ for Nutrition Products and Pyridine derivatives Nanjangud, Karnataka USFDA, AFSSAPS & PM DA approval APIs manufacturing facility Noida, Uttar Pradesh Corporate Office & R&D Centres Kirkland, Quebec, Canada USFDA approved facility for contract manufacturing Non Sterile products and Radiopharmaceuticals Salisbury, M aryland, USA USFDA approved facility for generics (Tablets & Capsules) Spokane, Washington, USA USFDA approved facility for contract manufacturing of Sterile injectable and Allergy Therapy Products Bedminster, New J ersey, USA Clinical Research Centre and Jubilant Life Sciences -M arketing Office Corporate Office Branch Offices M anufacturing Facilities R&D Facilities Indian Subsidiaries International Subsidiaries

Pune Hyderabad Chennai Lucknow

M erelbeke , Belgium Regulatory & Generic M arketing Shanghai, China M arketing Office

Not e: This illust rat ion is not exhaust ive. This illust rat ion is not t o scale

• Corporate Office and R&D Centres in Noida, India
• Discovery Centre in Bangalore, India
• 7 manufacturing facilities in India and 3 in North America

Dusseldorf, Germany Jubilant Clinsys, Europe office Ottawa, Canada DDDS office M alvern, Pennsylvania, USA DDDS Office Horsham, Pennsylvania Jubilant Cadista - Sales & M arketing Head Office Raleigh North Carolina, USA Clinical Research Centre and Jubilant Life Sciences M arketing Office

4

5 5

Key Financials

461 639 723 770 892 500 1000

FY08 FY09 FY10 FY11 FY12

106 124 175 127 186 100 200 300 FY08 FY09 FY10 FY11 FY12

US $ Mn US $ Mn

For FY 2012: 1 USD = 47.95 INR | | For FY 2011: 1 USD=44.60 | | For previous years : 1 USD=46.53

REVENUE EBITDA

Sustained growth momentum

6

Business Segments

Jubilant Life Sciences

Life Science Ingredients

M ix: 49%

Life Science Chemicals M ix: 22% Proprietary & Nutrition Ingredients M ix: 27% APIs, Generics, Specialty M ix: 30% CM O & CRO M ix: 21%

Presence across the Value Chain in Pharmaceuticals and Life Science Ingredients

6

Pharmaceuticals

M ix: 51%

6

7

Profile Growth Drivers

• Focus Areas
• APIs & Generics – CNS & CVS
• Radiopharmaceuticals – diagnostic products
• CM O - sterile injectibles, non sterile products
• Key growth markets – Regulated international markets
• Clients
• Diversified client base
• Products
• Diversified product base
• USFDA approved manufacturing facilities in
• India, US

A, Canada

• Strong product pipeline
• 135 launches globally over 3 years
• 58 DM F and 50 ANDAs filed in US
• Geographic expansion
• Europe, Japan, Emerging markets
• Penetration in North America
• Increased capacity utilization
• In APIs, Generics, CM O -sterile injectibles
• Clinical Trials
• CM O - extended service offerings in lab

trials for commercial products

• DDDS - Collaborative programs in discovery

& development

Business Segments

Pharmaceuticals Segment – Profile & Growth drivers

Offering products and services in niche segments for top-end clients

7

8

Profile Growth Drivers

• Offers Products for Industrial applications
• Pharmaceuticals & Agrochemicals
• Personal care, Food and Feed
• Packaging, Textiles, Dyes, Inks
• Vertically integrated in-house technology
• Green feedstock for value added end products
• Proprietary Products and Exclusive S

ynthesis – Pyridines & derivatives

• Nutrition Ingredients – Niacinamide (vitamin B3)
• Key growth markets – Europe, Emerging M arkets
• GM P compliant M anufacturing facilities in India
• Clients
• Diversified client base
• Proprietary Products and Exclusive Synthesis -

product launches including

• S

ymtet, Pyridine based ingredient for insecticide

• Geographic expansion
• Europe, US

A, China & ROW

• Higher Capacity Utilization
• Nutrition Ingredients - Vitamin B3 for

Animal & Human Nutrition

• Proprietary Products and Exclusive

S ynthesis – S ymtet, Pyridines

• Life Science Chemicals - Ethyl Acetate &

Acetic Anhydride

• Ongoing R&D of new product applications for

future growth

Business Segments

Life Science Ingredients Segment – Profile & Growth drivers

Integrated player with low cost manufacturing for the Ingredients market

8

9

Global leadership in chosen lines of business

Pharmaceuticals

• APIs – Globally No. 1 in 4 APIs; and ranked among T
• p 3 in 3 APIs
• Generics - No. 1 in US in 3 products ; and ranked among T
• p 3 in 5 products
• Radiopharmaceuticals – No. 1 in North America in 3 Nuclear M edicine products
• Allergy Immunotherapy - Ranked among top 3 suppliers in North America
• CM O – Ranked among top 5 Contract M anufacturers in North America in sterile injectibles

Life Science Ingredients

• PPES - Globally No. 1 in Pyridines & 14 derivatives
• Nutrition Ingredients - Globally No. 2 in Niacinamide
• Life Science Chemicals - Globally No. 7 in Ethyl Acetate and Acetic Anhydride

Leadership Positions in Niche M arkets

9

10

Strategic Objectives

• Global leadership in chosen lines of business
• Expanding innovative product portfolio, strengthened by in-house R&D
• Expanding geographic outreach
• Creating and pursuing growth opportunities
• High growth, high margin defensive Pharmaceuticals business
• Vertical integration
• Sustainability through Green initiatives
• Higher returns to shareholders

10

Expanding Product portfolio

11

Nutrition Ingredients Niacinamide, Niacin

Creating and pursuing growth opportunities

Value Addition through Vertical Integration

Life Science Chemicals Alcohol (own production / purchased) M ethanol, Acetaldehyde, Formaldehyde

Life Science Ingredients

Proprietary Products and Exclusive Synthesis Pyridines, Derivatives, Symtet, Beta Picoline, 3-Cyano Pyridine, >40 advance intermediates APIs (own production / purchased)

Pharmaceuticals

Vertical Integration enables cost competitive advantage and higher margins

Generics

11 11

12

Innovation & Continuous Improvement

• Expertise in development of non-

infringing processes for APIs and Dosage forms

• Strong IPR and Regulatory Affairs
• High skill and low cost operation
• Large number of process patent

applications filed

• Three-platform technologies

developed for taste masking, orally disintegrating, and delayed release

• Ability to do specialized formulations

and design equipments for radiopharmaceuticals

• Improvement in efficiency norms
• World class supply chain management

leading to reduced working capital

• Operational improvement through

employee participation

• Investment in R&D for new

product/ process development

• Capacity increase through de-

bottlenecking

Culture of Innovation Continuous cost improvements

Providing innovative products and economically efficient solutions

12

13

Lean management & Six Sigma

• Removing process inefficiencies
• Addressing process variation
• Alignment to customer requirement
• Improve plant effectiveness & asset utilization through Total Productivity

M anagement

M anufacturing Excellence Design Excellence Customer Excellence

Business Excellence Continuous Improvement Culture & Quality

Project M anagement

• Effective time and cost management for customer’s new product development

projects Customer dashboard & forecasting

• Analytics for better business decision making and forecasting accuracy

Design for Six Sigma (DFSS)

• Cut in cycle time of product development and process development

Amongst the lowest cost producers globally for most products in our portfolio

13

14

Creating and pursuing growth opportunities Corporate Sustainability

Sustainability Strategy Triple Bottom line Approach of Economic, Environment and Social Performance Global Reporting Initiative (GRI)

• Rated A+ by GRI for six consecutive years, highest possible rating
• T
• p 2 in India as per Carbon Disclosure Project 2010- India 200 Report

Green Products*

• Green Products are produced in ecologically beneficial way
• Customer’s first preference to bring more value through lower GHG emissions
• JLL Revenue from Green Products at 37% of Revenues in FY12, expected to grow at

a CAGR of over 18% between FY12-FY15 * Green Products are produced with lower eco-footprints as compared to alternative route, done mainly through use of eco-friendly raw materials, potential reuse of wastes, bio-energy and cogeneration

Sustainability through Green Initiatives

14

15

Corporate social responsibility is the commitment of businesses to contribute towards inclusive growth

Mission & Purpose

• T
• contribute towards improving the quality of life of the community around its

manufacturing locations and develop mutual trust and cordial relationships

• T
• bring more focus to this area of social interventions, Jubilant Bhartia Foundation, a not for

profit company was launched in 2007 to carryout various social initiatives

• As a part of the Jubilant Bhartia Group, the foundation focuses on conceptualizing and

implementing the Corporate Social Responsibility initiatives for the group

Corporate S

• cial Responsibility at Jubilant

15

16

• Recognizing and rewarding

Indian Social entrepreneurs in collaboration with Schwab Foundation

• Providing scholarships in R&D

and technology sector

National and International level

M anufacturing locations (with community)

Objective Action

• Philanthropic mode to

Community development mode

• Initiatives in line with M DGs

(M illennium Development Goals)

Fulfilling the role of a responsible corporate citizen by contributing towards inclusive growth

Inclusive Growth

Ultimate Goal

Winning the trust of the community

CSR Spectrum

CS R S pectrum

16

17 17

Primary Education

• JBF initiated Muskaan proj ect for

strengthening the Government Rural Primary Education system at all manufacturing locations

• Recognized by District

Administration

• Proj ect extended to 100 schools
• Reaching out to 13,500 students;

benefitting 65 S chools.

• Absenteeism dropped by 70%
• Dropout rate has declined

drastically

• A sense of pride among villagers

for having Muskaan school in their villages

Basic Healthcare

• To promote health seeking

behaviour and provide effective basic healthcare to the community JBF initiated Health Proj ects at all Location catering 4,85,000 beneficiaries:

• Initiated community based

pilot proj ect ‘ S wasthya Prahari’ in Public- Private- People Partnership (4P Model)

• ‘ Nirog Bachpan’ - S

chool health check-up programme

• Mobile/ S

tatic Clinic at all proj ect locations for Basic diagnostic services, Basic medication and referrals Day Care facilities, DOTS for TB, ICTC for HIV

Livelihood Generation

• JBF has structured its

livelihood framework for improving employability skills

• f youth.
• The four domains of the

training programs catering to the individual needs are:

• Technical Literacy
• Vocational Training
• Life S

kill Training

• S

ubsistence Living Training

• Vocational Training Centres at

all locations.

• Capacity to train 2000 youths

every year for skill development

• Employment: 60%

through S elf employment and placement

Social Entrepreneur

• f the Year Award
• The Jubilant Bhartia

Foundation and The S chwab Foundation for S

• cial

Entrepreneurship collaborating annually since 2010 to select India‘ s ‘ S

• cial

Entrepreneur of The Year’

• S
• cial Entrepreneurs are

innovators who implement practical and sustainable solutions to address challenges in numerous areas including health, education, environment, access to technology and j ob creation

• Mr. Anshu Gupta, Goonj ,

conferred with the Social Entrepreneur of the Year India 2012

An initiative between CII and Jubilant Bhartia to build capacity while leveraging technology and innovation to improve productivity and the environmental footprint of agriculture

18

Our Vision & Values

Our Values

18

19

Updated in May 2013

Thank You

Corporate Office 1-A, S ector-16A Noida-201301, UP, India Email:support@ j ubl.com For more Info : www.jubl.com 19